Haleon (HLN) to Release Earnings on Thursday

Haleon (NYSE:HLN) is expected to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Haleon to post earnings of $0.2512 per share and revenue of $2.7637 billion for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 3:45 AM ET.

Haleon Stock Up 1.3%

Shares of HLN stock traded up $0.15 during mid-day trading on Friday, hitting $11.26. The stock had a trading volume of 7,366,103 shares, compared to its average volume of 7,263,187. The firm has a market capitalization of $50.12 billion, a P/E ratio of 28.86 and a beta of 0.19. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.87 and a quick ratio of 0.63. Haleon has a 12-month low of $8.71 and a 12-month high of $11.42. The firm’s 50-day moving average is $10.35 and its two-hundred day moving average is $9.77.

Analysts Set New Price Targets

Several research analysts have issued reports on HLN shares. Deutsche Bank Aktiengesellschaft cut shares of Haleon from a “hold” rating to a “sell” rating in a report on Monday, January 12th. Morgan Stanley reaffirmed an “overweight” rating on shares of Haleon in a research report on Monday, December 15th. HSBC raised shares of Haleon from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 21st. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a report on Thursday, January 22nd. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Haleon in a research report on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Haleon presently has an average rating of “Moderate Buy” and an average target price of $12.33.

Hedge Funds Weigh In On Haleon

Institutional investors and hedge funds have recently bought and sold shares of the company. Morgan Stanley increased its position in shares of Haleon by 16.0% during the fourth quarter. Morgan Stanley now owns 21,495,383 shares of the company’s stock worth $217,318,000 after purchasing an additional 2,962,856 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Haleon by 116.7% in the 2nd quarter. Bank of America Corp DE now owns 12,384,135 shares of the company’s stock worth $128,423,000 after purchasing an additional 6,669,923 shares in the last quarter. Bank of Montreal Can grew its stake in Haleon by 454.1% during the 4th quarter. Bank of Montreal Can now owns 8,500,496 shares of the company’s stock worth $85,940,000 after buying an additional 6,966,416 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its position in Haleon by 4,315.4% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 8,027,189 shares of the company’s stock valued at $81,155,000 after buying an additional 7,845,391 shares in the last quarter. Finally, Nuveen LLC raised its stake in Haleon by 2.7% in the fourth quarter. Nuveen LLC now owns 6,169,355 shares of the company’s stock valued at $62,372,000 after buying an additional 159,955 shares during the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.